Fresh Funding For Lung Injury, IPF Drug Candidate
Idiopathic Pulmonary Fibrosis, News
Pharmaceutical company Lung Therapeutics recently announced an initial closing of $1,550,000 on its Series A Preferred Stock financing, which is comprised of $550,000 in converted debt, as well as a remaining funding of $1,200,000 ... Read more